OR WAIT null SECS
Three months following his departure from FDA, former commissioner Scott Gottlieb joins Pfizer’s board of directors.
Former FDA Commissioner Scott Gottlieb has joined the board of directors of Pfizer. The company announced the appointment in a June 27, 2019 statement, noting that Gottlieb will join the board’s Regulatory and Compliance Committee and the Science and Technology Committee.
In his term as commissioner from May 2018 to April 2019, FDA set records for approvals of new and generic drugs, introduced changes to clinical manufacturing processes, pushed for advances in manufacturing processes, and lead efforts to fight the opioid epidemic and deter the use of vaping products by teenagers.
Earlier in his career, Gottlieb worked at FDA as deputy commissioner for Medical and Scientific Affairs and as senior advisor to the FDA commissioner.
Following his tenure as FDA commissioner, he returned to his role as resident fellow at the American Enterprise Institute, a public policy think tank. Previously, Gottlieb served as a senior advisor at the Centers for Medicare and Medicaid Services and was a clinical assistant professor and physician.
“We are fortunate to have Dr. Gottlieb join Pfizer’s Board of Directors,” stated Ian Read, Pfizer executive chairman, in the press statement. “Scott’s expertise in health care, public policy and the industry will be an asset to our company and enable our shareholders to continue to benefit from a Board representing a balance of experience, competencies and perspectives.”
“We welcome Dr. Gottlieb to Pfizer’s Board of Directors,” said Albert Bourla, Pfizer chief executive officer in the press statement. “Through his work as a physician and his time at the FDA, Scott has continually demonstrated an understanding of both patients’ needs and the rapidly changing dynamics of biopharmaceutical research and development.”